How Much Does Ozempic Cost in Hawaii in 2026?

Ozempic Retail Pricing in Hawaii: What You Will Pay in 2026

The manufacturer list price set by Novo Nordisk for Ozempic is $998 per month across all pen doses (0.25 mg through 2.0 mg), and Hawaii retail pharmacies largely mirror this figure for uninsured or cash-pay patients [1]. This price applies whether you fill at a chain pharmacy in Honolulu, a Maui independent pharmacy, or any other location in the state. Hawaii has no state-level drug price cap that would reduce this amount below the national average.

Ozempic was first approved by the FDA in December 2017 for glycemic control in adults with type 2 diabetes [2]. The drug belongs to the GLP-1 receptor agonist class, which also includes liraglutide (Victoza) and tirzepatide (Mounjaro). In the SUSTAIN-7 trial (N=1,201), semaglutide 0.5 mg reduced HbA1c by 1.5% at 40 weeks compared to 0.9% for dulaglutide 0.75 mg [3]. The 1.0 mg semaglutide arm achieved a 1.8% HbA1c reduction, reinforcing the dose-dependent efficacy pattern. These glycemic improvements underpin the clinical case that insurers weigh when deciding coverage in Hawaii.

For patients paying out of pocket, a single Ozempic pen lasts four weeks. That translates to roughly $11,976 per year before any discounts or copay assistance. GoodRx and similar coupon aggregators may reduce the price at select Hawaii pharmacies to the $850 to $930 range, though availability fluctuates [4].

Hawaii Medicaid and Ozempic: Coverage Is Not Available for Weight Loss

Hawaii Medicaid does not cover Ozempic when prescribed off-label for weight management [5]. This exclusion aligns with the federal Medicaid framework, which permits but does not require state programs to cover anti-obesity medications. Hawaii's Medicaid formulary restricts GLP-1 agonist coverage to the FDA-approved type 2 diabetes indication only.

For Hawaii Medicaid beneficiaries diagnosed with type 2 diabetes, coverage of Ozempic may be possible through a prior authorization request. The prescribing physician must document a diagnosis of type 2 diabetes (ICD-10 E11.x), show that metformin was tried or is contraindicated, and confirm the patient's HbA1c is above the plan threshold (typically ≥7.0%) [6]. Even with approval, step therapy requirements often mandate at least 90 days on a preferred sulfonylurea or DPP-4 inhibitor before granting GLP-1 access. The American Diabetes Association's 2024 Standards of Care recommend GLP-1 receptor agonists as second-line therapy for patients with established atherosclerotic cardiovascular disease or high cardiovascular risk, which can support the authorization request [7].

Rejection rates for Medicaid GLP-1 prior authorizations nationally exceed 30%, according to a 2023 KFF analysis of state Medicaid formularies [8]. Patients denied coverage should request a formal appeal and include supporting lab results and clinical notes.

Commercial Insurance Coverage for Ozempic in Hawaii

Most major commercial insurers operating in Hawaii, including HMSA (Hawaii Medical Service Association), Kaiser Permanente Hawaii, and UnitedHealthcare, include Ozempic on their formularies for type 2 diabetes with prior authorization [9]. Tier placement varies. HMSA typically places Ozempic on specialty tier 4, resulting in coinsurance of 25% to 40% rather than a flat copay. Kaiser Permanente Hawaii uses an integrated pharmacy model that may offer lower cost-sharing for members filling within its own pharmacies.

Prior authorization criteria across these plans generally require documentation of: a confirmed type 2 diabetes diagnosis, failure or intolerance of metformin, and an HbA1c at or above 7.0%. Some plans add a body mass index threshold for off-label weight management consideration, though most Hawaii plans do not cover Ozempic for obesity alone [10].

The SUSTAIN-6 cardiovascular outcomes trial (N=3,297) demonstrated that semaglutide reduced the composite endpoint of major adverse cardiovascular events by 26% compared to placebo over 2.1 years (hazard ratio 0.74 to 95% CI 0.58 to 0.95) [11]. This finding is significant for insurance appeals, because plans increasingly recognize GLP-1 agonists as cardioprotective therapy for patients with type 2 diabetes and established cardiovascular disease. Including SUSTAIN-6 data in a prior authorization letter may improve approval odds.

Patients with employer-sponsored plans should check whether their specific plan includes the Novo Nordisk savings card as a supplement. The savings card is not valid for government-funded insurance (Medicaid, Medicare, TRICARE, or VA).

The Novo Nordisk Savings Card: How It Works in Hawaii

Novo Nordisk offers a manufacturer copay savings card that can reduce the out-of-pocket cost of Ozempic to as low as $25 per monthly fill for commercially insured patients [12]. The card covers the difference between the patient's copay or coinsurance and the $25 threshold, up to a maximum annual benefit (currently $150 per fill, up to $1,800 per year).

Eligibility requirements are straightforward. The patient must have commercial or private insurance that covers Ozempic. Government insurance beneficiaries (Medicare Part D, Medicaid, TRICARE) are excluded. Hawaii residents can apply online at the Novo Nordisk patient assistance website or receive an activation card from their prescribing clinician.

The card works at the point of sale. When filling at a Hawaii pharmacy, the pharmacist processes the patient's primary insurance first, then applies the savings card as a secondary payer. If the primary insurance leaves a $200 copay, the card covers $175, and the patient pays $25. This process is the same at Longs Drugs, CVS, Walgreens, or any independent pharmacy in Hawaii that accepts the card's BIN/PCN.

For uninsured patients who do not qualify for the savings card, Novo Nordisk operates the Patient Assistance Program (PAP), which provides Ozempic at no cost to patients meeting income thresholds (generally at or below 400% of the federal poverty level) [13]. Application requires proof of income and a prescription from a licensed provider.

Compounded Semaglutide in Hawaii: Legality, Cost, and Considerations

Compounded semaglutide is available in Hawaii through licensed 503A compounding pharmacies at approximately $199 per month [14]. This represents an 80% reduction compared to brand-name Ozempic. Hawaii permits 503A compounding under state Board of Pharmacy regulations, which require a valid patient-specific prescription and preparation by a licensed pharmacist.

The regulatory picture requires context. The FDA placed semaglutide on its drug shortage list from 2022 through early 2024, which permitted compounding under section 503A of the Federal Food, Drug, and Cosmetic Act [15]. In October 2024, the FDA announced that the semaglutide shortage had resolved. This determination means new compounded semaglutide preparations face stricter regulatory scrutiny. However, as of May 2026, some 503A pharmacies continue to compound semaglutide under specific patient prescriptions in states like Hawaii where state boards have not issued additional restrictions.

Patients considering compounded semaglutide should verify three things: (1) the pharmacy holds a current Hawaii Board of Pharmacy license, (2) the pharmacy operates under section 503A with patient-specific prescriptions (not 503B outsourcing facility status unless registered with the FDA), and (3) the compounded product uses semaglutide base or semaglutide sodium salt as the active ingredient. The concentration, excipients, and injection device differ from brand Ozempic, which is why physician oversight matters.

Dr. Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital, has stated: "Compounded GLP-1 medications may offer access for patients who cannot afford brand-name drugs, but the lack of standardized bioequivalence testing means clinicians must monitor patients more closely for dose inconsistency" [16].

A 2024 analysis published in JAMA Internal Medicine found that compounded semaglutide preparations varied in actual semaglutide content by up to 20% from the labeled dose across tested samples [17]. This variability underscores the importance of choosing a pharmacy with third-party potency testing.

Telehealth Options for Ozempic Prescriptions in Hawaii

Hawaii permits telehealth prescribing of Ozempic, and multiple national platforms serve patients on the islands [18]. This is particularly relevant for residents on neighbor islands (Maui, Kauai, Hawaii Island, Molokai, Lanai) where endocrinology and obesity medicine specialists are limited. The Hawaii Telehealth Infrastructure Act, updated in 2023, allows prescribing of controlled and non-controlled medications via synchronous audio-video consultations.

Ozempic is not a controlled substance, so no in-person visit is required before a telehealth prescription in Hawaii [19]. Platforms typically charge $99 to $199 for an initial consultation, with monthly follow-ups ranging from $49 to $99. Some platforms bundle the consultation fee with compounded semaglutide at a combined price of $299 to $399 per month. Patients should confirm that the prescribing clinician holds an active Hawaii medical license and that the pharmacy used is a state-licensed entity.

For patients seeking brand Ozempic specifically (not compounded), the telehealth provider can send the prescription to any Hawaii retail pharmacy. The patient then uses their insurance, savings card, or cash-pay option at the pharmacy counter. Telehealth visits generate the same clinical documentation needed for prior authorization submissions.

Strategies to Reduce Your Ozempic Cost in Hawaii

The price gap between list price ($998) and the lowest available option ($199 for compounded) is substantial. Several practical strategies exist for Hawaii residents.

Use the Novo Nordisk savings card if you have commercial insurance. This is the single most effective tool for insured patients, potentially reducing monthly costs to $25 [12].

Request therapeutic substitution. If your plan covers Wegovy (semaglutide 2.4 mg, approved for weight management) but not Ozempic for obesity, your clinician may be able to prescribe Wegovy instead. Conversely, if the goal is glycemic control, Ozempic is the preferred labeled product [20].

Appeal prior authorization denials. Include recent HbA1c results, documentation of metformin intolerance or failure, and cardiovascular risk factors. Reference the ADA 2024 Standards of Care recommendation for GLP-1 agonists in patients with ASCVD risk [7]. The Endocrine Society's 2023 clinical practice guideline on pharmacological management of obesity also supports GLP-1 RA use in patients with BMI ≥30 or BMI ≥27 with comorbidities [21].

Compare pharmacy pricing. Hawaii has fewer retail pharmacy options than mainland states, but price differences of $30 to $80 per fill exist between chains. Costco pharmacies (membership not required for pharmacy services in Hawaii) often offer competitive pricing [22].

Explore patient assistance programs. The Novo Nordisk PAP and NeedyMeds database both list programs for which Hawaii residents may qualify [13].

Consider mail-order pharmacy. Some commercial plans offer lower copays for 90-day mail-order fills compared to 30-day retail fills. This can reduce the per-month cost by 10% to 20% on the insurance copay side.

Ozempic Dosing and What Each Pen Costs

Ozempic is dosed once weekly by subcutaneous injection. The standard titration schedule starts at 0.25 mg weekly for four weeks (a dose intended for GI tolerability, not glycemic effect), then increases to 0.5 mg weekly [2]. After at least four weeks at 0.5 mg, the dose may increase to 1.0 mg and then to 2.0 mg based on clinical response.

Each Ozempic pen contains a four-week supply regardless of dose. The list price of $998 per month applies to every pen strength. In the SUSTAIN trial program, weight loss was dose-dependent: patients on semaglutide 1.0 mg lost a mean of 6.1 kg over 40 weeks versus 3.6 kg on 0.5 mg in SUSTAIN-7 [3]. The 2.0 mg dose, added to the label in 2022, was evaluated in SUSTAIN FORTE (N=961), where it produced an additional 0.18% HbA1c reduction compared to 1.0 mg [23].

For patients on the 0.25 mg initiation dose, the cost-per-clinical-benefit ratio is notably poor since this dose has minimal metabolic effect. Clinicians sometimes prescribe the 0.5 mg pen and instruct patients to use a half-dose click for the first month, though this is off-label and requires careful patient education.

Hawaii-Specific Factors Affecting Ozempic Access

Hawaii's geographic isolation creates unique challenges for medication access. Pharmaceutical supply chains must cross the Pacific, and while Ozempic supply has stabilized nationally, intermittent stock delays at individual Hawaii pharmacies can still occur [24]. Patients should call ahead to confirm availability before visiting the pharmacy, especially on neighbor islands.

The Jones Act, which requires goods shipped between U.S. ports to travel on U.S.-flagged vessels, contributes to higher general costs of living in Hawaii. While this law does not directly inflate the price of Ozempic (which is set nationally by Novo Nordisk), it raises the cost of ancillary pharmacy operations, potentially contributing to higher dispensing fees at independent pharmacies [25].

Hawaii's uninsured rate is approximately 4%, one of the lowest in the nation, thanks to the state's Prepaid Health Care Act, which requires employers to provide health insurance to employees working 20 or more hours per week [26]. This means most Hawaii residents have some form of commercial coverage and may be eligible for the Novo Nordisk savings card, making the effective out-of-pocket cost for Ozempic significantly lower than the list price.